Cargando…
Gemcitabine-induced skin necrosis
Since its emergence as a chemotherapy agent, gemcitabine has been associated with cutaneous adverse reactions. Rash is reported to be the most common cutaneous adverse effect. Other reported cutaneous reactions in the literature include bullous dermatosis, pseudocellulitis, subacute cutaneous lupus...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6207959/ https://www.ncbi.nlm.nih.gov/pubmed/30397477 http://dx.doi.org/10.1177/2050313X18809268 |
_version_ | 1783366620331114496 |
---|---|
author | Haydock, Maria Monica Sigdel, Saroj Pacioles, Toni |
author_facet | Haydock, Maria Monica Sigdel, Saroj Pacioles, Toni |
author_sort | Haydock, Maria Monica |
collection | PubMed |
description | Since its emergence as a chemotherapy agent, gemcitabine has been associated with cutaneous adverse reactions. Rash is reported to be the most common cutaneous adverse effect. Other reported cutaneous reactions in the literature include bullous dermatosis, pseudocellulitis, subacute cutaneous lupus alopecia, and palmar–plantar erythrodysesthesia. Skin necrosis is a very rare adverse effect of this otherwise well-tolerated chemotherapeutic agent. In searching the literature, only one other case has been reported. In our report, we present a 74-year-old male with adenocarcinoma of the pancreas, status-post pancreaticoduodenectomy (Whipple procedure), who developed a rare case of skin necrosis of the lower leg 2 weeks after completing six cycles of monotherapy gemcitabine treatment. |
format | Online Article Text |
id | pubmed-6207959 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-62079592018-11-05 Gemcitabine-induced skin necrosis Haydock, Maria Monica Sigdel, Saroj Pacioles, Toni SAGE Open Med Case Rep Case Report Since its emergence as a chemotherapy agent, gemcitabine has been associated with cutaneous adverse reactions. Rash is reported to be the most common cutaneous adverse effect. Other reported cutaneous reactions in the literature include bullous dermatosis, pseudocellulitis, subacute cutaneous lupus alopecia, and palmar–plantar erythrodysesthesia. Skin necrosis is a very rare adverse effect of this otherwise well-tolerated chemotherapeutic agent. In searching the literature, only one other case has been reported. In our report, we present a 74-year-old male with adenocarcinoma of the pancreas, status-post pancreaticoduodenectomy (Whipple procedure), who developed a rare case of skin necrosis of the lower leg 2 weeks after completing six cycles of monotherapy gemcitabine treatment. SAGE Publications 2018-10-30 /pmc/articles/PMC6207959/ /pubmed/30397477 http://dx.doi.org/10.1177/2050313X18809268 Text en © The Author(s) 2018 http://www.creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Case Report Haydock, Maria Monica Sigdel, Saroj Pacioles, Toni Gemcitabine-induced skin necrosis |
title | Gemcitabine-induced skin necrosis |
title_full | Gemcitabine-induced skin necrosis |
title_fullStr | Gemcitabine-induced skin necrosis |
title_full_unstemmed | Gemcitabine-induced skin necrosis |
title_short | Gemcitabine-induced skin necrosis |
title_sort | gemcitabine-induced skin necrosis |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6207959/ https://www.ncbi.nlm.nih.gov/pubmed/30397477 http://dx.doi.org/10.1177/2050313X18809268 |
work_keys_str_mv | AT haydockmariamonica gemcitabineinducedskinnecrosis AT sigdelsaroj gemcitabineinducedskinnecrosis AT paciolestoni gemcitabineinducedskinnecrosis |